Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Weight loss pills are generally safe when taken under proper medical supervision with awareness of potential side effects.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The introduction of the Orphan Drug ... approval of new medicines for rare diseases, although the speed of this change was slow, despite of the positive trend, for example there were 6 folds increase ...

This image provided by Eli Lilly shows the company’s new Alzheimer’s drug Kisunla. (Eli Lilly and Company via AP) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] A European ...

March 28, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran ... of Non-Malignant Hematology in the FDA's Center for Drug Evaluation and Research.

Fitusiran (Qfitlia; Sanofi) was approved by the FDA as a subcutaneous ... the Division of Non-Malignant Hematology in the FDA’s Center for Drug Evaluation and Research, said in a statement.

March 28 (Reuters) - The U.S. Food and Drug Administration approved French drugmaker Sanofi's (SASY.PA), opens new tab hemophilia therapy, introducing a new type of treatment administered every ...